Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2021
ASCO 2021
Straight after its first cancer bispecific OK, J&J highlights two more at ASCO
Pharmaforum
Tue, 05/25/21 - 10:59 am
JNJ
ASCO 2021
talquetamab
teclistamab
Genmab
Janssen
Multiple Myeloma
ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal
Fierce Biotech
Fri, 05/21/21 - 11:52 am
Boehringer Ingelheim
OSE Immunotherapeutics
immuno-oncology
BI 765063
ASCO 2021
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs: a look ahead at ASCO
BioPharma Dive
Thu, 05/20/21 - 11:18 pm
ASCO 2021
Allogene
CAR-T
Bristol Myers Squibb
EQRx
ASCO 2021 – Guardant shoots for the moon
EP Vantage
Thu, 05/20/21 - 11:12 pm
ASCO 2021
Guardant Health
liquid biopsy
colorectal cancer
ASCO 2021: Watch for Sanofi/Sloan Kettering, Incyte, Exelixis and AstraZeneca
BioSpace
Thu, 05/20/21 - 12:35 pm
ASCO 2021
Sanofi
Sloane Kettering
Incyte
AstraZeneca
Exelixis
oncology
#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over
Endpoints
Thu, 05/20/21 - 12:21 pm
ASCO 2021
JNJ
amivantamab
non-small cell lung cancer
#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data
Endpoints
Thu, 05/20/21 - 12:16 pm
ASCO 2021
Astellas
Seagen
Padcev
FDA
urothelial cancer
ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
Fierce Pharma
Thu, 05/20/21 - 12:15 pm
ASCO 2021
Ipsen
Exelixis
Cabometyx
thyroid cancer
clinical trials
Bristol Myers details data for closely watched cancer immunotherapy
BioPharma Dive
Wed, 05/19/21 - 11:27 pm
ASCO 2021
immunotherapy
Bristol Myers Squibb
Opdivo
skin cancer
relatlimab
ASCO: Sanofi says early amcenestrant data could see it be 'endocrine backbone therapy' in breast cancer
Fierce Biotech
Wed, 05/19/21 - 11:24 pm
ASCO 2021
Sanofi
breast cancer
Amcenestrant
ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas
Fierce Biotech
Wed, 05/19/21 - 11:22 pm
Adaptimmune
ASCO 2021
sarcomas
soft tissue sarcomas
clinical trials
Takeda fleshes out case for oral EGFR drug with follow-up pivotal data in non-small cell lung cancer
Endpoints
Wed, 05/19/21 - 11:14 pm
ASCO 2021
lung cancer
Takeda
FDA
non-small cell lung cancer
Allogene sets out to prove that their off-the-shelf approach to CAR-T can beat the personalized approach
Endpoints
Wed, 05/19/21 - 11:11 pm
ASCO 2021
Allogen
blood cancer
CAR-T
Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone
Endpoints
Wed, 05/19/21 - 11:10 pm
Merck
Keytruda
ASCO 2021
Pages
« first
‹ previous
1
2